Clinical Trial · NCT02978586

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Overview

The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called \[Ga-68\]PSMA.

Sponsor

Case Comprehensive Cancer Center

Contacts

Norbert Avril, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02978586

Drug / Compound

PSMA

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients able to tolerate PET/MRI scans
Patients with PSMA-positive tumors including prostate cancer, breast cancer, lung cancer, and other tumor types know to express PSMA

Exclusion

Subjects who do not meet the above mentioned inclusion criteria
Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks.
Patients who have a history of serious adverse events related to a previous MRI or PET/CT
Renal insufficiency: elevated Creatinine and/or Glomerular Filtration Rate (GFR)\<40ml/min/1.7sqm (exclusion criterion only for contrast enhanced MRI)
Patients who are currently pregnant or breast feeding. A pregnancy test within 72 hours of the first PET/MRI will be performed.
Patients with a known allergy against any component of the contrast enhancing MR agent will not receive MR contrast agents. (exclusion criterion only for contrast enhanced MRI)